Ultragenyx Pharmaceutical Inc. Stock News

Strengthens balance sheet with non-dilutive capital at an attractive cost

Piper Sandler cut The Goldman Sachs Group, Inc. (NYSE: GS) price target from $430 to $410. Goldman Sachs shares fell 0.1% to $296.79 in pre-market trading. Benchmark lowered Western Digital Corpora

Shares of Mereo BioPharma (MREO) surge after reports suggest that AstraZeneca (AZN) is interested in acquiring it.

Ultragenyx is a rare disease drug developer. Its execution, so far, has been near perfect.

The FDA grants orphan drug and rare pediatric disease designations to Ionis' (IONS) ION582 for treating Angelman syndrome. These designations will help incentivize development of the candidate.

NOVATO, Calif., June 10, 2022 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for s

NOVATO, Calif., June 10, 2022 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for ser

NOVATO, Calif., June 01, 2022 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for ser

Ultragenyx Pharmaceutical (NASDAQ:RARE) has observed the following analyst ratings within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 1 4 1 0

Ultragenyx (RARE) signs an exclusive license agreement with Abeona Therapeutics to acquire the latter's gene therapy candidate, ABO-102 (now UX111), for treating Sanfilippo syndrome type A.

Ultragenyx (RARE) signs an exclusive license agreement with Abeona Therapeutics to acquire the latter's gene therapy candidate, ABO-102 (now UX111), for treating Sanfilippo syndrome type A.

Get ahead of the market by subscribing to Seeking Alpha's Stocks to Watch, a preview of key events scheduled for the coming week

Citigroup has decided to maintain its Buy rating of Ultragenyx Pharmaceutical (NASDAQ:RARE) and lower its price target from $150.00 to $146.00. Shares of Ultragenyx Pharmaceutical are trading up 2.9%

Ultragenyx (RARE) reports wider-than-expected loss in the first quarter of 2022 while revenues miss estimates.

Analysts have provided the following ratings for Ultragenyx Pharmaceutical (NASDAQ:RARE) within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 0